Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients

Liver International

Volumn 37, Issue 4, 2017, Pages 534-541

  Eletreby, Rasha ^a   Elakel, Wafaa ^a   Said, Mohamed ^a   El Kassas, Mohamed ^b   Seif, Sameh ^c   Elbaz, Tamer ^a   El Raziky, Maissa ^a   Abdel Rehim, Siham ^d   Zaky, Samy ^e   Fouad, Rabab ^a   Gamal Eldeen, Hadeel ^a   Abdo, Mahmoud ^a   Korany, Mohamed ^f   Yosry, Ayman ^a   El Serafy, Magdy ^a   El Sayed, Manal Hamdy ^g   ElShazly, Yehia ^h   Waked, Imam ⁱ   Doss, Wahid ^a   Esmat, Gamal ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b HELWAN UNIVERSITY   (Egypt)

^c NATIONAL HEPATOLOGY AND TROPICAL MEDICINE RESEARCH INSTITUTE   (Egypt)

^d ALEXANDRIA UNIVERSITY   (Egypt)

^e AL AZHAR UNIVERSITY   (Egypt)

^f Cairo Fatemic Hospital   (Egypt)

^g AIN SHAMS UNIVERSITY   (Egypt)

^h AIN SHAMS UNIVERSITY   (Egypt)

ⁱ National Liver Institute   (Egypt)

Author keywords

efficacy; HCV genotype IV; safety; Sofosbuvir Simeprevir

Indexed keywords

ALBUMIN; HEMOGLOBIN; SIMEPREVIR; SOFOSBUVIR; ANTIVIRUS AGENT;

ADULT; ALBUMIN BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; CONTROLLED STUDY; CREATININE CLEARANCE; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EGYPTIAN; FEMALE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; INSOMNIA; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; PERSONAL EXPERIENCE; PHOTOSENSITIVITY; PRURITUS; RASH; SUSTAINED VIROLOGIC RESPONSE; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; EGYPT; GENETICS; GENOTYPE; HEPACIVIRUS; LIVER CIRRHOSIS; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TREATMENT FAILURE; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; EGYPT; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; SEVERITY OF ILLNESS INDEX; SIMEPREVIR; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE; TREATMENT FAILURE; VIRAL LOAD;

EID: 84997207228     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13266     Document Type: Article

References (24)

1. Estes C, Abdel-Kareem M, Abdel-Razek W, et al. Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies. Aliment Pharmacol Ther. 2015;42:696–706.
2. Esmat G. Hepatitis C in the Eastern Mediterranean Region. East Mediterr Health J 2013;19:587–588.
3. El-Zanaty F, Way A. Egypt Demographic and Health Survey 2008. Cairo, Egypt: Ministry of Health, El-Zanaty and Associates, and Macro International; 2009. Ann. http://www.measuredhs.com.
4. Mokdad AA, Lopez AD, Shahraz S, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med. 2014;12:145–169.
5. Doss W, Shiha G, Hassany M, et al. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol. 2015;63:581–585.
6. Stedman C. Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential. Therap Adv Gastroenterol. 2014;7:131–140.
7. Robertson B, Myers G, Howard C, et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch Virol. 1998;143:2493–2503.
8. Cholongitasa E, Papatheodoridis GV. Sofosbuvir: a novel oral agent for chronic hepatitis C. Ann Gastroenterol. 2014;27:331–337.
9. Centre for Disease Control and Prevention. Morbidity and Mortality Weekly Report (MMWR). 2012, MMWR/Vol. 61/No. 29.
10. Kandeel A, Genedy M, El-Refai S, Funk A, Fontanet A, Talaat M. The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment. Liver Int. 2017;37:45–53.
11. Gaetano JN. Benefit-risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir. Drug Healthc Patient Saf. 2014;6:37–45.
12. World health organization (WHO) guidelines for the screening, care and treatment of persons with chronic hepatitis C infection, Updated version, April, 2016. Guidelines.
13. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis patients with HIV/HCV co-infection. Hepatology. 2006;43:1317–1325.
14. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014;384:1756–1765.
15. El Raziky M, Gamil M, Hammad R, et al. Treatment of Hepatitis C Genotype 4 patients with Simeprevir and Sofosbuvir: Preliminary Results from a Phase IIa, Partially Randomised, Open-label Trial conducted in Egypt (OSIRIS). Abstract ID: 1163. OSIRIS poster, presented at the Liver Meeting®, the Annual Meeting of the American Association for the Study of Liver Diseases. 2015.
16. Willemse SB, Baak LC, Kuiken SD, et al. Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life. J Viral Hepatitis 2016; 23:950–954.
17. El-Khayat HR, Fouad YM, Maher M, El–Amin H, Muhammed H. Efficacy and safety of sofosbuvir plus simeprevir therapy in Egyptian patients with chronic hepatitis C: a real-world experience. 2016 Gut gutjnl -312012Published Online First: 10 August 2016
18. Moreno C, Hezode C, Marcellin P, et al. Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4. J Hepatol. 2015;62:1047–1055.
19. Hezode C, Hirschfield GM, Ghesquiere W, et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection. Gut. 2015;64:948–956.
20. Hassanein T, Sims KD, Bennett M, et al. A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection. J Hepatol. 2015;62:1204–1206.
21. Dieterich D, Bacon BR, Flamm SL, et al. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population. Hepatology. 2014;60:220A.
22. Abdel-Razek W, Waked I. Optimal therapy in genotype 4 chronic hepatitis C: finally cured? Liver Int. 2015;35(Suppl. 1):27–34.
23. Kanda T, Nakamoto Sh, Sasaki R, et al. Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin. Int J Med Sci. 2016;13:310–315.
24. Ruane PJ, Ain D, Stryker R, et al. Sofosbuvir plus ribavirinfor the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry EASL. J Hepatol. 2015;62:1040–1046.